This information is intended only for healthcare professionals resident in the United Kingdom


Prescribing Information (PI) for COMIRNATY ®KP.2 ▼(cemivameran) COVID-19 mRNA vaccine and COMIRNATY ®LP.8.1 ▼(mRNA encoding LP.8.1) COVID-19 mRNA vaccine and COMIRNATY ®JN.1 ▼(bretovameran) COVID-19 mRNA vaccine

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

United Kingdom

Header

This text is for block level content. P tags can go in here too

COMIRNATY KP.2 30 micrograms/dose dispersion for injection, multidose vial COVID-19 mRNA Vaccine ready for use, 12+ years - PI for UK

COMIRNATY LP.8.1 10 micrograms/dose dispersion for injection single dose vial, COVID-19 mRNA Vaccine ready for use children 5 to 11 years - PI for UK

COMIRNATY LP.8.1 3 micrograms/dose concentrate for dispersion for injection 3-dose vial, COVID-19 mRNA Vaccine dilute before use 6 months to 4 years - PI for UK

Comirnaty JN.1 30 micrograms/dose dispersion for injection, multidose vial COVID-19 mRNA Vaccine ready for use 12+ years - PI for UK

Comirnaty JN.1 10 micrograms/dose dispersion  for injection, single dose vial COVID-19 mRNA Vaccine ready for use children 5 to 11 years - PI for UK

Comirnaty JN.1 3 micrograms/dose concentrate for  dispersion for injection, 3-dose vial COVID-19 mRNA Vaccine dilute before use 6 months to 4 years - PI for UK

PP-CMR-GBR-0902 I August 2025